SCHEMBL5219725

SCHEMBL5219725

Cc1cc(Cl)nc(C2CC2)n1

nearest known ligand 0.52

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 15/20 0.52
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.36
CHRM3 P20309 2/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16682873 0.92 PDE10A (0.44) PDE10ALMNAHTTCHRM3PDE4A
SCHEMBL18821775 0.88 PDE10A (0.42) PDE10ALMNAHTTCHRM3PDE4A
SCHEMBL13033012 0.84 PDE10A (0.50) PDE10ALMNAHTTCHRM3PDE4A
SCHEMBL1286211 0.84 PDE10A (0.50) PDE10ACHRM3PDE4APDE4BPDE4C
Propane SCHEMBL10853768 0.84 PDE10A (0.39) PDE10AKMT2A
SCHEMBL31568039 0.81 GSK3A (0.39) PDE10ALMNAHTT
SCHEMBL30809426 0.78 MAPT (0.34) PDE10ALMNAHTT
SCHEMBL24500132 0.77 PDE10A (0.43) PDE10ALMNAHTTCHRM3PDE4A
SCHEMBL21211777 0.77 PDE10A (0.43) PDE10ACHRM3PDE4APDE4BPDE4C
SCHEMBL19894137 0.77 PDE10A (0.43) PDE10AKMT2ACHRM3PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174662-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES CILAG AG (CH) 2024-05-30 US disclosed
US-20240158392-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES JANSSEN RESEARCH & DEVELOPMENT, LLC 2024-05-16 US disclosed
EP-4284801-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES Janssen Biotech, Inc. (US) 2023-12-06 EP disclosed
EP-4284802-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES Janssen Biotech, Inc. (US) 2023-12-06 EP disclosed
EP-3784667-B1 HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2023-08-16 EP disclosed
EP-3784667-B1 HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2023-08-16 EP disclosed
US-11708369-B2 Heteroaromatic compounds having activity against RSV Janssen Sciences Ireland Unlimited Company (IE) 2023-07-25 US disclosed
US-11708369-B2 Heteroaromatic compounds having activity against RSV Janssen Sciences Ireland Unlimited Company (IE) 2023-07-25 US disclosed
US-11708369-B2 Heteroaromatic compounds having activity against RSV Janssen Sciences Ireland Unlimited Company (IE) 2023-07-25 US disclosed
WO-2022165530-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES JANSSEN BIOTECH, INC. (US) 2022-08-04 WO disclosed
US-20210094958-A1 HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV Janssen Sciences Ireland Unlimited Company (IE) 2021-04-01 US disclosed
US-20210094958-A1 HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV Janssen Sciences Ireland Unlimited Company (IE) 2021-04-01 US disclosed
EP-3784667-A1 HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV Janssen Sciences Ireland Unlimited Company (IE) 2021-03-03 EP disclosed
CN-112004815-A Heteroaromatic compounds with activity against RSV 爱尔兰詹森科学公司 2020-11-27 CN disclosed
CN-107108637-B Triazolopyrimidine compound and application thereof NOVARTIS AG (CH) 2019-10-29 CN disclosed
CN-109790166-A imidazopyridine compounds for the treatment of cancer 诺华股份有限公司 2019-05-21 CN disclosed
CN-107108637-A Triazolopyrimidine compound and application thereof 诺华股份有限公司 2017-08-29 CN disclosed
CN-1882568-B Pyrrol derivatives with antibacterial activity ASTRAZENECA AB 2012-03-28 CN disclosed
EP-1664025-B1 PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY ASTRAZENECA AB (SE) 2007-09-19 EP disclosed
CN-1882568-A Pyrrol derivatives with antibacterial activity ASTRAZENECA AB (SE) 2006-12-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158392-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES SIK2, SIK1, SGK2 PDE10A 2065/4885LMNA 2925/4885HTT 3602/4885
US-20210094958-A1 HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV MAVS, ZC3HAV1, SARS1 PDE10A 4644/4885LMNA 2405/4885HTT 1346/4885
US-20240174662-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES SIK2, SIK1, SGK2 PDE10A 1926/4885LMNA 2773/4885HTT 3979/4885
US-11708369-B2 Heteroaromatic compounds having activity against RSV MAVS, ZC3HAV1, SARS1 PDE10A 4644/4885LMNA 2405/4885HTT 1346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.